Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL)

  1. Eisfeld, Hannah
  2. Kircher, Stefan
  3. Rosenwald, Andreas
  4. Anagnostopoulos, Ioannis
  5. Werner, Mathias
  6. Gaßler, Nikolaus
  7. Wolf, Gunter
  8. Lehmkuhl, Lukas
  9. Teichgräber, Ulf
  10. Gühne, Falk
  11. Darr, Andreas
  12. Freesmeyer, Martin
  13. Weschenfelder, Wolfram
  14. Hofmann, Gunther
  15. Dalkilic, Ramazan
  16. Kalff, Rolf
  17. Hochhaus, Andreas
  18. Schrenk, Karin ORCID logo

Download
s00277-020-04247-4.pdf 5,34MB
WeightNameValue
1000 Titel
  • Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL)
1000 Autor/in
  1. Eisfeld, Hannah |
  2. Kircher, Stefan |
  3. Rosenwald, Andreas |
  4. Anagnostopoulos, Ioannis |
  5. Werner, Mathias |
  6. Gaßler, Nikolaus |
  7. Wolf, Gunter |
  8. Lehmkuhl, Lukas |
  9. Teichgräber, Ulf |
  10. Gühne, Falk |
  11. Darr, Andreas |
  12. Freesmeyer, Martin |
  13. Weschenfelder, Wolfram |
  14. Hofmann, Gunther |
  15. Dalkilic, Ramazan |
  16. Kalff, Rolf |
  17. Hochhaus, Andreas |
  18. Schrenk, Karin |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-08
1000 Erschienen in
1000 Quellenangabe
  • 100(4):1107-1109
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00277-020-04247-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960597/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • For most acute myeloid leukemia (AML) patients, an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of sustained remissions and long-term survival. At diagnosis, high expression of the AML-associated genes BAALC (brain and acute leukemia, cytoplasmic) and MN1 (meningioma-1) were repeatedly linked to inferior outcomes in patients consolidated with chemotherapy while data for patients receiving HSCT remain limited. Using clinically applicable digital droplet PCR assays, we analyzed the diagnostic BAALC/ABL1 and MN1/ABL1 copy numbers in 302 AML patients. High BAALC/ABL1 and MN1/ABL1 copy numbers associated with common adverse prognostic factors at diagnosis. However, while high diagnostic copy numbers of both genes associated with shorter event free survival (EFS) and overall survival (OS) in patients receiving chemotherapy, there was no prognostic impact in patients undergoing HSCT. Our data suggests that the adverse prognostic impact of high BAALC and MN1 expression are mitigated by allogeneic HSCT. But preHSCT BAALC/ABL1 and MN1/ABL1 assessed in remission prior to HSCT remained prognosticators for EFS and OS independent of the diagnostic expression status. Whether allogeneic HSCT may improve survival for AML patients with high diagnostic BAALC or MN1 expression should be investigated prospectively and may improve informed decisions towards individualized consolidation options in AML.
1000 Sacherschließung
lokal Female [MeSH]
lokal Lymphoma, Large-Cell, Anaplastic/diagnostic imaging [MeSH]
lokal Anaplastic Lymphoma Kinase/metabolism [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Positron Emission Tomography Computed Tomography [MeSH]
lokal Cyclophosphamide/therapeutic use [MeSH]
lokal Lymphoma, Large-Cell, Anaplastic/pathology [MeSH]
lokal Letter to the Editor
lokal Oncology
lokal Etoposide/therapeutic use [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Hematology
lokal Prednisolone/therapeutic use [MeSH]
lokal Magnetic Resonance Imaging [MeSH]
lokal Lymphoma, Large-Cell, Anaplastic/drug therapy [MeSH]
lokal Ki-1 Antigen/metabolism [MeSH]
lokal Vincristine/therapeutic use [MeSH]
lokal Lymphoma, Large-Cell, Anaplastic/diagnosis [MeSH]
lokal Doxorubicin/therapeutic use [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RWlzZmVsZCwgSGFubmFo|https://frl.publisso.de/adhoc/uri/S2lyY2hlciwgU3RlZmFu|https://frl.publisso.de/adhoc/uri/Um9zZW53YWxkLCBBbmRyZWFz|https://frl.publisso.de/adhoc/uri/QW5hZ25vc3RvcG91bG9zLCBJb2Fubmlz|https://frl.publisso.de/adhoc/uri/V2VybmVyLCBNYXRoaWFz|https://frl.publisso.de/adhoc/uri/R2HDn2xlciwgTmlrb2xhdXM=|https://frl.publisso.de/adhoc/uri/V29sZiwgR3VudGVy|https://frl.publisso.de/adhoc/uri/TGVobWt1aGwsIEx1a2Fz|https://frl.publisso.de/adhoc/uri/VGVpY2hncsOkYmVyLCBVbGY=|https://frl.publisso.de/adhoc/uri/R8O8aG5lLCBGYWxr|https://frl.publisso.de/adhoc/uri/RGFyciwgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/RnJlZXNtZXllciwgTWFydGlu|https://frl.publisso.de/adhoc/uri/V2VzY2hlbmZlbGRlciwgV29sZnJhbQ==|https://frl.publisso.de/adhoc/uri/SG9mbWFubiwgR3VudGhlcg==|https://frl.publisso.de/adhoc/uri/RGFsa2lsaWMsIFJhbWF6YW4=|https://frl.publisso.de/adhoc/uri/S2FsZmYsIFJvbGY=|https://frl.publisso.de/adhoc/uri/SG9jaGhhdXMsIEFuZHJlYXM=|https://orcid.org/0000-0003-2131-6779
1000 Hinweis
  • DeepGreen-ID: 4f6882dc6b154034be679ddba238019d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6467008.rdf
1000 Erstellt am 2023-11-17T05:26:58.975+0100
1000 Erstellt von 322
1000 beschreibt frl:6467008
1000 Zuletzt bearbeitet Fri Dec 01 05:19:09 CET 2023
1000 Objekt bearb. Fri Dec 01 05:19:09 CET 2023
1000 Vgl. frl:6467008
1000 Oai Id
  1. oai:frl.publisso.de:frl:6467008 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source